One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve.

ABSTRACT:

Importance

Bioprosthetic mitral valves are implanted with increasing frequency but inevitably degenerate, leading to heart failure. Reoperation is associated with high morbidity and mortality. Transcatheter mitral valve-in-valve (MViV) using balloon-expandable transcatheter valves has emerged as an alternative for high-surgical risk patients.

Objective

To assess contemporary outcomes of SAPIEN 3 (Edwards Lifesciences) MViV replacement.

Design, setting, and participants

In this registry-based prospective cohort study of SAPIEN 3 MViV, patients entered in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry from June 2015 to July 2019 were analyzed. US Centers for Medicare and Medicaid linkage ensured comprehensive collect

SUBMITTER: Whisenant B 

PROVIDER: S-EPMC7391176 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature